Peptide-based immunotherapy, Antigens-Combinations-Translation (#52)
Juliane S. Walz1
1 Tübingen, Department of Internal Medicine, KKE Transnationale Immunologie, University Hospital Tübingen, Tübingen, Baden-Württemberg, Germany
The clinical success of T-cell based immunotherapy approaches including advances in allogeneic stem cell transplantation, checkpoint inhibitors and adoptive T-cell transferhave broad a revolution to the treatment of several malignancies. Remaining challenges lie in guiding the specificity and increasing the frequency of anti-tumor immune responses, reducing toxicities and expanding the spectrum of targetable entities. A rational and promising approach to achieve this goal is peptide-based immunotherapy, which represents a low side-effect immunotherapy approach relying on specific immune recognition of tumor-associated HLA-presented peptides. In recent years our group worked on the direct mass spectrometric analysis of the immunopeptidome of hematological and solid malignancies with the aim to (I) identify and further characterize novel naturally presented tumor-associated antigens including mutation-derived neoepitopes, to (II) evaluated the influence of different cancer drugs on the immunopeptidome of tumor cells to identify so called “treatment-induced” antigen targets and to (III) finally translate these experimental results into clinical peptide-based immunotherapy concepts for cancer patients (e.g. iVAC-CLL01 study, NCT02802943).
Keywords: Immunotherapy, HLA ligandome, T cells, Peptide vaccination